0.2150SEK-1.38%Mkt Cap: 13.84M SEKP/E: —Last update: 2026-06-01
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. T…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap13.84M SEK
Enterprise Value13.65M SEK
Revenue (TTM)47.00K SEK
Gross Profit47.00K SEK
Net Income (TTM)-6.93M SEK
Revenue/Share0.0010 SEK
Last Price0.2150 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue290.45
P/S298.52
P/B2.02
EPS (TTM)-0.12
EPS (Forward)—
52W Range
0.027430% of range0.6460
52W High0.6460 SEK
52W Low0.0274 SEK
Profitability
Gross Margin100.00%
Oper. Margin-14836.17%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-100.09%
ROA-80.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.72M SEK
CapEx (TTM)—
FCF Margin-8884.33%
FCF Yield-30.18%
Net Debt-1.60M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity12.28
Current Ratio3.50
Quick Ratio3.16
Book Value/Sh0.1080 SEK
Cash/Share0.0380 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.64.36M
Float56.45M
Insiders21.52%
Institutions21.41%
Technical
SMA 500.1701 (+26.4%)
SMA 2000.2192 (-1.9%)
Beta-0.88
S&P 52W Chg27.70%
Avg Vol (30d)6.34M
Avg Vol (10d)1.43M
Technical Indicators
RSI (14)52.1
MACD0.0231
MACD Signal0.0284
MACD Hist.-0.0053
BB Upper0.4260 SEK
BB Middle0.2218 SEK
BB Lower0.0176 SEK
BB Width184.13%
ATR (14)0.0640 SEK
Vol Ratio (20d)0.09x